Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05328557 · ClinicalTrials.gov registry record · Phase 1
A Phase Ia Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Subcutaneously Administered CUG252 in Normal Healthy Volunteers
A Phase 1 study, sponsored by Cugene.
- Completed
- Registry status
- Phase 1
- Development phase
- 32
- Enrollment target
NCT05328557 is a Phase 1 study that has completed, run by Cugene. The registered enrollment target is 32 participants.
The verdict
NCT05328557, a Phase 1 study, has completed, sponsored by Cugene.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 32 participants
- Enrollment target
Study Summary
The intent of this study is to evaluate the safety and tolerability of single escalating subcutaneous doses of CUG252 in healthy adult subjects.
Interventions
- DRUG Placebo
- DRUG CUG252
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2021-11-09 |
| Est. Completion | 2022-08-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05328557
The ClinicalTrials.gov registry entry for NCT05328557 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 32 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Cugene, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT05328557 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05328557 about?
NCT05328557 is a clinical study titled "A Phase Ia Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Subcutaneously Administered CUG252 in Normal Healthy Volunteers". The intent of this study is to evaluate the safety and tolerability of single escalating subcutaneous doses of CUG252 in healthy adult subjects.
What is the current status of trial NCT05328557?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 32 participants. The study started on 2021-11-09. Estimated completion is 2022-08-03.
What interventions are being tested in trial NCT05328557?
The interventions under investigation include: Placebo (DRUG), CUG252 (DRUG).
Who is sponsoring clinical trial NCT05328557?
This trial is sponsored by Cugene, which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.